{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:06:41Z","timestamp":1779080801017,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04305-7","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:52:15Z","timestamp":1775746335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Melittin enhances PD-L1 blockade in prostate cancer by inhibiting M2 macrophage polarization and recruitment"],"prefix":"10.1186","volume":"24","author":[{"given":"Rucheng","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanquan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"1","key":"4305_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"4305_CR2","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023;389(16):1453\u201365.","journal-title":"N Engl J Med"},{"key":"4305_CR3","doi-asserted-by":"publisher","first-page":"217155","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett. 2024;601:217155.","journal-title":"Cancer Lett"},{"issue":"1","key":"4305_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14(1):663.","journal-title":"Nat Commun"},{"issue":"6186","key":"4305_CR5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344(6186):921\u20135.","journal-title":"Science"},{"issue":"3","key":"4305_CR6","doi-asserted-by":"publisher","first-page":"e2303894","DOI":"10.1002\/advs.202303894","volume":"11","author":"H Xiao","year":"2024","unstructured":"Xiao H, Du X, Tao Z, et al. Taurine Inhibits Ferroptosis Mediated by the Crosstalk between Tumor Cells and Tumor-Associated Macrophages in Prostate Cancer. Adv Sci (Weinh). 2024;11(3):e2303894.","journal-title":"Adv Sci (Weinh)"},{"issue":"8048","key":"4305_CR7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637(8048):1207\u201317.","journal-title":"Nature"},{"issue":"10","key":"4305_CR8","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/1078-0432.CCR-22-3350","volume":"29","author":"K Chaudagar","year":"2023","unstructured":"Chaudagar K, Hieromnimon HM, Khurana R, et al. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN\/p53-deficient Prostate Cancer. Clin Cancer Res. 2023;29(10):1952\u201368.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"4305_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/pros.24605","volume":"83","author":"R Yan","year":"2023","unstructured":"Yan R, Dai W, Mao Y, et al. Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL-17 signaling pathway gene LCN2 in castration-resistant prostate cancer. Prostate. 2023;83(15):1430\u201345.","journal-title":"Prostate"},{"key":"4305_CR10","doi-asserted-by":"publisher","first-page":"215615","DOI":"10.1016\/j.canlet.2022.215615","volume":"534","author":"R Yan","year":"2022","unstructured":"Yan R, Dai W, Wu R, Huang H, Shu M. Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. Cancer Lett. 2022;534:215615.","journal-title":"Cancer Lett"},{"issue":"11","key":"4305_CR11","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.3748\/wjg.v22.i11.3186","volume":"22","author":"GM Kong","year":"2016","unstructured":"Kong GM, Tao WH, Diao YL, et al. Melittin induces human gastric cancer cell apoptosis via activation of mitochondrial pathway. World J Gastroenterol. 2016;22(11):3186\u201395.","journal-title":"World J Gastroenterol"},{"issue":"21","key":"4305_CR12","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.3390\/ijms252111686","volume":"25","author":"K Wang","year":"2024","unstructured":"Wang K, Tao L, Zhu M, et al. Melittin Inhibits Colorectal Cancer Growth and Metastasis by Ac-Tivating the Mitochondrial Apoptotic Pathway and Suppressing Epithelial-Mesenchymal Transition and Angiogenesis. Int J Mol Sci. 2024;25(21):11686.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4305_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40360-021-00503-z","volume":"22","author":"P Askari","year":"2021","unstructured":"Askari P, Namaei MH, Ghazvini K, Hosseini M. In vitro and in vivo toxicity and antibacterial efficacy of melittin against clinical extensively drug-resistant bacteria. BMC Pharmacol Toxicol. 2021;22(1):42.","journal-title":"BMC Pharmacol Toxicol"},{"key":"4305_CR14","doi-asserted-by":"publisher","first-page":"217772","DOI":"10.1016\/j.canlet.2025.217772","volume":"625","author":"X Bai","year":"2025","unstructured":"Bai X, Guo YR, Zhao ZM, et al. Macrophage polarization in cancer and beyond: from inflammatory signaling pathways to potential therapeutic strategies. Cancer Lett. 2025;625:217772.","journal-title":"Cancer Lett"},{"issue":"6","key":"4305_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41419-024-06756-w","volume":"15","author":"Y Cui","year":"2024","unstructured":"Cui Y, Chen C, Tang Z, et al. TREM2 deficiency aggravates renal injury by promoting macrophage apoptosis and polarization via the JAK-STAT pathway in mice. Cell Death Dis. 2024;15(6):401.","journal-title":"Cell Death Dis"},{"key":"4305_CR16","doi-asserted-by":"publisher","first-page":"217758","DOI":"10.1016\/j.canlet.2025.217758","volume":"626","author":"W Li","year":"2025","unstructured":"Li W, Wei H, Liu J, et al. Exosomal Biglycan promotes gastric cancer progression via M2 polarization and CXCL10-mediated JAK\/STAT1 activation. Cancer Lett. 2025;626:217758.","journal-title":"Cancer Lett"},{"key":"4305_CR17","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3389\/fimmu.2018.02629","volume":"9","author":"D Argyle","year":"2018","unstructured":"Argyle D, Kitamura T. Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors. Front Immunol. 2018;9:2629.","journal-title":"Front Immunol"},{"issue":"12","key":"4305_CR18","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.3390\/s22124577","volume":"22","author":"F Mulita","year":"2022","unstructured":"Mulita F, Verras GI, Anagnostopoulos CN, Kotis K. A Smarter Health through the Internet of Surgical Things. Sens (Basel). 2022;22(12):4577.","journal-title":"Sens (Basel)"},{"issue":"12","key":"4305_CR19","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cancers17121969","volume":"17","author":"A Mulita","year":"2025","unstructured":"Mulita A, Valsamaki P, Bekou E, et al. Benefits from (18)F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study. Cancers (Basel). 2025;17(12):1969.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4305_CR20","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y, Baryawno N, Severe N, et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021;39(11):1464\u2013e14788.","journal-title":"Cancer Cell"},{"issue":"1","key":"4305_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40880-019-0425-1","volume":"39","author":"X Zhang","year":"2019","unstructured":"Zhang X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. Cancer Commun (Lond). 2019;39(1):76.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"4305_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.trecan.2024.01.004","volume":"10","author":"DH Angappulige","year":"2024","unstructured":"Angappulige DH, Mahajan NP, Mahajan K. Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression. Trends Cancer. 2024;10(4):369\u201381.","journal-title":"Trends Cancer"},{"issue":"5","key":"4305_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14712598.2022.2027904","volume":"22","author":"I Mitsogiannis","year":"2022","unstructured":"Mitsogiannis I, Tzelves L, Dellis A, Issa H, Papatsoris A, Moussa M. Prostate cancer immunotherapy. Expert Opin Biol Ther. 2022;22(5):577\u201390.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"4305_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/cancers14020440","volume":"14","author":"C Martori","year":"2022","unstructured":"Martori C, Sanchez-Moral L, Paul T, et al. Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance. Cancers (Basel). 2022;14(2):440.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4305_CR25","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41423-024-01216-z","volume":"21","author":"A Mantovani","year":"2024","unstructured":"Mantovani A, Marchesi F, Di Mitri D, Garlanda C. Macrophage diversity in cancer dissemination and metastasis. Cell Mol Immunol. 2024;21(11):1201\u201314.","journal-title":"Cell Mol Immunol"},{"key":"4305_CR26","doi-asserted-by":"publisher","first-page":"110505","DOI":"10.1016\/j.intimp.2023.110505","volume":"121","author":"WM Hu","year":"2023","unstructured":"Hu WM, Liu SQ, Zhu KF, et al. The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK\/STAT and inhibits pancreatic cancer invasion and metastasis. Int Immunopharmacol. 2023;121:110505.","journal-title":"Int Immunopharmacol"},{"key":"4305_CR27","doi-asserted-by":"publisher","first-page":"155311","DOI":"10.1016\/j.phymed.2023.155311","volume":"124","author":"Y Yan","year":"2024","unstructured":"Yan Y, Zhang LB, Ma R, et al. Jolkinolide B ameliorates rheumatoid arthritis by regulating the JAK2\/STAT3 signaling pathway. Phytomedicine. 2024;124:155311.","journal-title":"Phytomedicine"},{"key":"4305_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2017.05.010","volume":"402","author":"I Rady","year":"2017","unstructured":"Rady I, Siddiqui IA, Rady M, Mukhtar H. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett. 2017;402:16\u201331.","journal-title":"Cancer Lett"},{"key":"4305_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jconrel.2024.08.047","volume":"375","author":"X Duan","year":"2024","unstructured":"Duan X, Zou H, Yang J, Liu S, Xu T, Ding J. Melittin-incorporated nanomedicines for enhanced cancer immunotherapy. J Control Release. 2024;375:285\u201399.","journal-title":"J Control Release"},{"issue":"2","key":"4305_CR30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/cancers16020282","volume":"16","author":"F Cersosimo","year":"2024","unstructured":"Cersosimo F, Lonardi S, Ulivieri C, et al. CSF-1R in Cancer: More than a Myeloid Cell Receptor. Cancers (Basel). 2024;16(2):282.","journal-title":"Cancers (Basel)"},{"key":"4305_CR31","doi-asserted-by":"publisher","first-page":"105072","DOI":"10.1016\/j.critrevonc.2025.105072","volume":"218","author":"F Hajibabaie","year":"2026","unstructured":"Hajibabaie F, Abedpoor N, Maleki B, et al. Targeting the CCL2\/CCR2 axis in colorectal cancer: Immunopharmacological perspectives and therapeutic strategies. Crit Rev Oncol Hematol. 2026;218:105072.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4305_CR32","doi-asserted-by":"publisher","first-page":"1652166","DOI":"10.3389\/fimmu.2025.1652166","volume":"16","author":"IH Han","year":"2025","unstructured":"Han IH, Choi I, Kim S, Kwon M, Choi H, Bae H. Immunomodulatory peptide-drug conjugate MEL-dKLA suppresses progression of prostate cancer by eliminating M2-like tumor-associated macrophages. Front Immunol. 2025;16:1652166.","journal-title":"Front Immunol"},{"issue":"4","key":"4305_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/cmi.2017.135","volume":"15","author":"T Yoshimura","year":"2018","unstructured":"Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally. Cell Mol Immunol. 2018;15(4):335\u201345.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"4305_CR34","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/cas.14306","volume":"111","author":"T Masuda","year":"2020","unstructured":"Masuda T, Noda M, Kogawa T, et al. Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer. Cancer Sci. 2020;111(3):924\u201331.","journal-title":"Cancer Sci"},{"issue":"4","key":"4305_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.trecan.2024.12.003","volume":"11","author":"S Parvanian","year":"2025","unstructured":"Parvanian S, Ge X, Garris CS. Recent developments in myeloid immune modulation in cancer therapy. Trends Cancer. 2025;11(4):365\u201375.","journal-title":"Trends Cancer"},{"issue":"1","key":"4305_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s40425-019-0676-z","volume":"7","author":"W Gao","year":"2019","unstructured":"Gao W, Zhang X, Yang W, et al. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells. J Immunother Cancer. 2019;7(1):231.","journal-title":"J Immunother Cancer"},{"issue":"43","key":"4305_CR37","doi-asserted-by":"publisher","first-page":"eaay1863","DOI":"10.1126\/sciimmunol.aay1863","volume":"5","author":"L Strauss","year":"2020","unstructured":"Strauss L, Mahmoud M, Weaver JD, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5(43):eaay1863.","journal-title":"Sci Immunol"},{"issue":"2","key":"4305_CR38","doi-asserted-by":"publisher","first-page":"e2203973","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang B, Zhu J, Wang Y, et al. Targeted xCT-mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti-PD-1\/L1 Response. Adv Sci (Weinh). 2023;10(2):e2203973.","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"4305_CR39","first-page":"1973","volume":"6","author":"M Yang","year":"2021","unstructured":"Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973\u201387.","journal-title":"Bioact Mater"},{"issue":"8","key":"4305_CR40","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/pharmaceutics17081019","volume":"17","author":"J Rizkallah","year":"2025","unstructured":"Rizkallah J, Charbel N, Yassine A, et al. Melittin-Based Nanoparticles for Cancer Therapy: Mechanisms, Applications, and Future Perspectives. Pharmaceutics. 2025;17(8):1019.","journal-title":"Pharmaceutics"},{"key":"4305_CR41","doi-asserted-by":"publisher","first-page":"103198","DOI":"10.1016\/j.critrevonc.2020.103198","volume":"157","author":"M Ferro","year":"2021","unstructured":"Ferro M, Lucarelli G, Crocetto F, et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. Crit Rev Oncol Hematol. 2021;157:103198.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4305_CR42","doi-asserted-by":"publisher","first-page":"102992","DOI":"10.1016\/j.critrevonc.2020.102992","volume":"151","author":"C Buonerba","year":"2020","unstructured":"Buonerba C, Ferro M, Dolce P, et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;151:102992.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04305-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04305-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04305-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:20:02Z","timestamp":1779078002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04305-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4305"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04305-7","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Tongji University (TJBB08125103) and performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}